Éric Amela

596 total citations
18 papers, 418 citations indexed

About

Éric Amela is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Éric Amela has authored 18 papers receiving a total of 418 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 5 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in Éric Amela's work include Sarcoma Diagnosis and Treatment (4 papers), Renal cell carcinoma treatment (3 papers) and Oral and Maxillofacial Pathology (3 papers). Éric Amela is often cited by papers focused on Sarcoma Diagnosis and Treatment (4 papers), Renal cell carcinoma treatment (3 papers) and Oral and Maxillofacial Pathology (3 papers). Éric Amela collaborates with scholars based in France and Morocco. Éric Amela's co-authors include Nicolas Penel, Christine Chevreau, Perrine Marec‐Bérard, Y Robin, Gauthier Decanter, Stéphanie Clisant, Antoîne Italiano, Jean‐Yves Blay, Antoine Adenis and Frédéric Rolland and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Éric Amela

16 papers receiving 411 citations

Peers

Countries citing papers authored by Éric Amela

Since Specialization

Citations

This map shows the geographic impact of Éric Amela's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Amela with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Amela more than expected).

Fields of papers citing papers by Éric Amela

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Amela. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Amela. The network helps show where Éric Amela may publish in the future.

Co-authorship network of co-authors of Éric Amela

This figure shows the co-authorship network connecting the top 25 collaborators of Éric Amela. A scholar is included among the top collaborators of Éric Amela based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éric Amela. Éric Amela is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Shifting Paradigms in TNBC Treatment: Emerging Alternatives to Capecitabine in the Post-Neoadjuvant Setting 2024 ·Current Oncology ·(unknown), Amine Souadka, (unknown), Matteo Santoni, Nicola Battelli, Éric Amela, Antoine Lemaire, Joseph Rodriguez, Hassan Errihani	0
2	2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM) 2023 ·Annals of Oncology ·Philippe Barthélémy, Yohann Loriot, Aude Fléchon, M. Gross Goupil, Éric Voog, (unknown), Véronique Lorgis, Damien Pouessel, (unknown), Christophe Sajous, (unknown), Aline Guillot, (unknown), Éric Amela, Constant Josse, (unknown), (unknown), Constance Thibault	2
3	Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial 2018 ·BMC Cancer ·Diane Pannier, Antoine Adenis, Emilie Bogart, Éric Dansin, (unknown), (unknown), Anne Lesoin, Éric Amela, (unknown), (unknown), Marie‐Cécile Le Deley, Nicolas Penel	2
4	Predictors for malignant tissue (MT) in residual masses (RM) of non-seminomatous germ cell tumors (NSGCT) treated by chemotherapy (CT) before surgery. 2017 ·Journal of Clinical Oncology ·(unknown), Emmanuelle Bompas, Emilie Bogart, Fredrik Laestadius, Guillaume Mouillet, Friederike Schlürmann, Éric Leblanc, Nicolas Penel, Jean‐Pierre Lotz, Éric Amela	0
5	Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma 2016 ·Anticancer Research ·(unknown), Antoine Adenis, Olivier Bouché, Alain Duhamel, Alexandra Heurgué, Emmanuelle Leteurtre, Éric Amela, Julia Salleron, Mohamed Hebbar	22
6	Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma—Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study 2016 ·European Journal of Cancer ·Stéphane Oudard, Lionnel Geoffrois, Aline Guillot, Christine Chevreau, Jean‐Laurent Deville, (unknown), Helen Boyle, Marjorie Baciuchka, P. Gimel, Brigitte Laguerre, Mathieu Laramas, Christian Pfister, Delphine Topart, Frédéric Rolland, Éric Legouffe, (unknown), Éric Amela, Sophie Abadie‐Lacourtoisie, Marine Gross‐Goupil	29
7	Selection of ultimately ill cancer patients able to fulfill a questionnaire: Identification of inherent biases 2015 ·Bulletin du Cancer ·(unknown), Charles Fournier, Véronique Christophe, M. Reich, Stéphanie Villet, (unknown), Thomas Ryckewaert, (unknown), Éric Amela, G. Lefebvre, (unknown), Pascal Antoine, Nicolas Penel	1
8	Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO) 2015 ·Annals of Oncology ·Emmanuelle Bompas, Axel Le Cesne, Emmanuelle Tresch‐Bruneel, Loïc Lebellec, Valérie Laurence, Olivier Collard, Esma Saâda-Bouzid, Nicolás Isambert, Jean‐Yves Blay, Éric Amela, Sébastien Salas, Christine Chevreau, François Bertucci, Antoîne Italiano, Stéphanie Clisant, Nicolas Penel	82
9	Clinical Activity of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma (Mrcc) – Results of the Resume Study 2014 ·Annals of Oncology ·Stéphane Oudard, M. Gross Goupil, L. Geoffrois, Aline Guillot, Christine Chevreau, Jean‐Laurent Deville, Sławomir Falkowski, (unknown), (unknown), P. Gimel, Brigitte Laguerre, Mathieu Laramas, C. Pfister, (unknown), Frédéric Rolland, Éric Legouffe, Éric Amela, Sophie Abadie‐Lacourtoisie, Naim Al Mahi	6
10	A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours 2013 ·British Journal of Cancer ·Antoine Adenis, Isabelle Ray‐Coquard, Antoîne Italiano, Emmanuelle Chauzit, B. Bui-Nguyen, Jean‐Yves Blay, Emmanuelle Tresch‐Bruneel, Charles Fournier, Stéphanie Clisant, Éric Amela, Philippe A. Cassier, Mathiéu Molimard, Nicolas Penel	21
11	Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome 2013 ·BMC Cancer ·Antoine Adenis, Emmanuelle Tresch, S. Dewas, Olivier Romano, Mathieu Messager, Éric Amela, Stéphanie Clisant, Andrew Kramar, C. Mariette, X. Mirabel	29
12	Les cancers de l’ouraque 2013 ·Bulletin du Cancer ·(unknown), T. Ghoneim, Xavier Leroy, Éric Amela, (unknown), Stéphane Culine, Arnauld Villers, Antoine Adenis	5
13	A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group 2013 ·British Journal of Cancer ·Philippe A. Cassier, (unknown), Éric Amela, Christine Chevreau, B. Bui, A. Lecesne, Isabelle Ray‐Coquard, Sylvie Chabaud, Nicolas Penel, Yann Bergé, Julien Dômont, Antoîne Italiano, Florence Duffaud, (unknown), (unknown), Jean‐Yves Blay	58
14	A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases 2013 ·Clinical Genitourinary Cancer ·Christine Chevreau, Alain Ravaud, Bernard Escudier, Éric Amela, R. Delva, Frédéric Rolland, Diégo Tosi, Stéphane Oudard, Ellen Blanc, Céline Ferlay, Sylvie Négrier	57
15	Management of “unfavourable” carcinoma of unknown primary site: Synthesis of recent literature 2012 ·Critical Reviews in Oncology/Hematology ·Éric Amela, (unknown), Sophie Cousin, Thomas Ryckewaert, Antoine Adenis, Nicolas Penel	24
16	Solitary Fibrous Tumors and So-Called Hemangiopericytoma 2012 ·Sarcoma ·Nicolas Penel, Éric Amela, Gauthier Decanter, Y Robin, Perrine Marec‐Bérard	67
17	Efficacy and safety of panobinostat (LBH-589), a histone-deacetylase inhibitor (HDACi), in patients (pts) with advanced, previously treated soft tissue sarcoma (STS) and sex cord tumors (SCT): A study from the French Sarcoma Group. 2012 ·Journal of Clinical Oncology ·Philippe A. Cassier, (unknown), Nicolas Penel, Christine Chevreau, Binh Bui Nguyen, Axel Le Cesne, Isabelle Laure Ray-Coquard, Sylvie Chabaud, Éric Amela, Yann Bergé, Julien Dômont, Antoîne Italiano, Florence Duffaud, (unknown), (unknown), Jean‐Yves Blay	1
18	A simple predictive model for postoperative mortality after head and neck cancer surgery with opening of mucosa 2006 ·Oral Oncology ·Nicolas Penel, Éric Amela, Y. Mallet, (unknown), Stéphanie Clisant, (unknown), (unknown), (unknown), Jean‐Louis Lefebvre	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact